BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35344964)

  • 1. Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials.
    Singer M; Khanani AM; Wolf A; Flores R; Chhablani J; B G; Clemens A; Gedif K; Liu X; Mulyukov Z; Querques G
    Ophthalmologica; 2022; 245(4):315-322. PubMed ID: 35344964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Singh RP; Koh A; Ogura Y; Weissgerber G; Gedif K; Jaffe GJ; Tadayoni R; Schmidt-Erfurth U; Holz FG
    Ophthalmology; 2021 Jan; 128(1):89-99. PubMed ID: 32574761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials.
    Regillo C; Singh R; Hamilton R; Gedif K; Best C; Koh A; Holz FG
    Ophthalmologica; 2022; 245(5):403-412. PubMed ID: 35468601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
    Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
    Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
    Lally DR; Loewenstein A; Arnold JJ; Yang YC; Gedif K; Best C; Patel H; Tadayoni R; Heier JS
    Eye (Lond); 2023 Apr; 37(6):1242-1248. PubMed ID: 35597816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.
    Finger RP; Dennis N; Freitas R; Quenéchdu A; Clemens A; Karcher H; Souied EH
    Adv Ther; 2022 Aug; 39(8):3425-3448. PubMed ID: 35678996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HAWK Extension Study: Safety and Efficacy of Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration.
    Brown DM; Nowik M; Bouillaud E; Dugel APU;
    Curr Eye Res; 2023 Jan; 48(1):44-50. PubMed ID: 36398628
    [No Abstract]   [Full Text] [Related]  

  • 10. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
    Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
    J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data.
    Agostini H; Mulyukov Z; Tsilimbaris M; Calvo P; Bucher F; Gaucher D; Pigeolet E; Colafrancesco V; Clemens A
    Curr Eye Res; 2020 Oct; 45(10):1298-1301. PubMed ID: 32065533
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.
    Sadda S; Sarraf D; Khanani AM; Tadayoni R; Chang AA; Saffar I; Gedif K; Wong DT
    Br J Ophthalmol; 2024 May; 108(6):852-858. PubMed ID: 37669850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
    Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
    Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
    Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
    Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
    Mori R; Honda S; Gomi F; Tsujikawa A; Koizumi H; Ochi H; Ohsawa S; Okada AA;
    Jpn J Ophthalmol; 2023 May; 67(3):301-310. PubMed ID: 37039948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
    Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
    Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
    Brown DM; Emanuelli A; Bandello F; Barranco JJE; Figueira J; Souied E; Wolf S; Gupta V; Ngah NF; Liew G; Tuli R; Tadayoni R; Dhoot D; Wang L; Bouillaud E; Wang Y; Kovacic L; Guerard N; Garweg JG
    Am J Ophthalmol; 2022 Jun; 238():157-172. PubMed ID: 35038415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Treatment Agnostic Analysis of the HAWK and HARRIER Studies.
    Eichenbaum D; Brown DM; Ip M; Khanani AM; Figueroa MS; McAllister IL; Laude A; B G; Tang S; Gmeiner B; Clemens A; Souied E
    Retina; 2023 Apr; 43(4):632-640. PubMed ID: 36705252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies.
    Dugel PU; Jhaveri CD; Chakravarthy U; Wykoff CC; Singh RP; Hamilton R; Weissgerber G; Mulyukov Z; Holz FG
    Retina; 2022 Mar; 42(3):511-518. PubMed ID: 34923515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy.
    Ferrante N; Ritrovato D; Bitonti R; Furneri G
    BMC Health Serv Res; 2022 Apr; 22(1):573. PubMed ID: 35484540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.